TY - JOUR T1 - Correction: <em>Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study</em> JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1136/jitc-2019-000437corr1 VL - 8 IS - 2 SP - e000437corr1 A2 - , Y1 - 2020/07/01 UR - http://jitc.bmj.com/content/8/2/e000437corr1.abstract ER -